Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Regulator hits Victrex monopoly

by Alexander H. Tullo
May 9, 2016 | A version of this story appeared in Volume 94, Issue 19

Victrex has settled with the Federal Trade Commission over what the regulator sees as the British polyether ether ketone (PEEK) producer’s monopolistic behavior. FTC says Invibio, the Victrex subsidiary that sells the high-end polymer for medical implants, maintained its commanding 90% market share by forcing customers to sign exclusive contracts. Competitors Solvay and Evonik were locked out of the market. In a statement, Victrex points out that it didn’t have to admit to breaking the law and it will not be subjected to fines or penalties. It will, however, have to permit competition under existing and future contracts.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.